Product information and disease description Product description Product information

Average sales price and wholesale acquisition cost

7 evidence topics · 6 sources

Summary: announced, estimated, and comparator prices

As of 26 September 2026, Mirum Pharmaceuticals had announced no wholesale acquisition cost, list price, or average sales price for Atebrioz; the company stated that it would announce the price at the U.S. launch planned for October 2026. The only published price figure is an estimate of about $750,000 per year attributed by Reuters to a named Citizens analyst. The United Kingdom horizon-scanning briefing of July 2025 recorded the cost as not yet known. For the two other FDA-approved FOP therapies, Ipsen stated an average U.S. list price for Sohonos of $624,000 per year at its 2023 approval, and Regeneron stated an average annual U.S. list price for Pasatru of about $1.4 million, with a range of $693,000 to $2.1 million by dose and body weight. In the 2023 Canadian review, the submitted price of palovarotene was $324.22 (Canadian) per mg, corresponding to about $622,373 per year for patients younger than 14 years and $1,022,894 per year for patients aged 14 years and older.

United States wholesale acquisition cost and average sales price of zilurgisertib

“Mirum expects to launch the drug in October and plans to announce its price at the launch, CEO Chris Peetz told Reuters.” (opens the source at this quote in a new tab)

Analyst estimate of the annual price of zilurgisertib

“Citizens analyst Jonathan Wolleben estimates Atebrioz could cost about $750,000 annually and generate roughly $150 million in peak worldwide sales.” (opens the source at this quote in a new tab)

Estimated cost in the United Kingdom horizon scan

“Estimated Cost The cost of zilurgisertib is not yet known.” (opens the source at this quote in a new tab)

Comparator list price: Sohonos (palovarotene) in the United States

“Ipsen will sell the medicine under the brand name Sohonos at an average list price of $624,000 a year, though the cost will vary depending on insurance coverage, patient needs and support programs.” (opens the source at this quote in a new tab)

Comparator list price: Pasatru (garetosmab-grts) in the United States

“Pasatru will have an average annual, per-patient list price of about $1.4 million based on the enrollees in clinical studies, according to a Regeneron spokesperson. The drug is dosed at either 3 or 10 milligrams per kilogram of body weight, so the cost could total anywhere between $693,000 and $2.1 million, the spokesperson said.” (opens the source at this quote in a new tab)

Comparator price in Canada: palovarotene submitted price and annual cost

“Palovarotene is available as 1 mg, 1.5 mg, 2.5 mg, 5 mg, and 10 mg capsules at a submitted price of $324.22 per mg.” (opens the source at this quote in a new tab)

“Treatment with Sohonos is expected to cost approximately $1,022,894 per year for patients aged 14 years and older and $622,373 per year for patients younger than 14 years.” (opens the source at this quote in a new tab)